Bristol-Myers Squibb premarket stock declines 1.4% after reports confirm no discussions with AstraZeneca on a potential deal.
Bristol-Myers Squibb (BMY) fell 1.4% in premarket trading following a report that no discussions are underway with AstraZeneca (AZN) regarding a potential deal. AstraZeneca’s shares rose 5.6% in response.
Earlier speculation had suggested possible merger or partnership talks between the two pharmaceutical companies. No prior official statements confirmed active negotiations, though market expectations had fueled volatility in both stocks.
The report clarified that no deal was ever in progress, ending short-term speculation about a potential transaction.